Insulin degludec: a novel basal insulin analogue.

about

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.The past, present, and future of basal insulins.Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements.

P2860

Q38241834-D57285BC-25EB-4625-B2AD-89BB767528BE Q38618376-239B82EB-772A-4877-89D0-7BD6A7076F9D Q52606010-3A16F5C0-EEC8-4290-AF22-360CB420F28F

P2860

Insulin degludec: a novel basal insulin analogue.

Item

http://www.wikidata.org/entity/Q38079527

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Insulin degludec: a novel basal insulin analogue.

@en

type

Item

label

Insulin degludec: a novel basal insulin analogue.

@en

prefLabel

Insulin degludec: a novel basal insulin analogue.

@en

P1476

Insulin degludec: a novel basal insulin analogue.

@en

P2093

David M Schnee

http://www.w3.org/2001/XMLSchema#string

Dhiren K Patel

http://www.w3.org/2001/XMLSchema#string

Jennifer D Goldman-Levine

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

P304

269-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1R351

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235405859

http://www.w3.org/2001/XMLSchema#string

P698

23386075

http://www.w3.org/2001/XMLSchema#string

Insulin degludec: a novel basal insulin analogue.

about

P2860

P2860

Insulin degludec: a novel basal insulin analogue.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698